[go: up one dir, main page]

AR062239A1 - Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal - Google Patents

Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal

Info

Publication number
AR062239A1
AR062239A1 ARP070103482A ARP070103482A AR062239A1 AR 062239 A1 AR062239 A1 AR 062239A1 AR P070103482 A ARP070103482 A AR P070103482A AR P070103482 A ARP070103482 A AR P070103482A AR 062239 A1 AR062239 A1 AR 062239A1
Authority
AR
Argentina
Prior art keywords
angiogenesis
organs
animal
human
retinal neovascularization
Prior art date
Application number
ARP070103482A
Other languages
English (en)
Original Assignee
Civil De Estudios Superiores A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civil De Estudios Superiores A filed Critical Civil De Estudios Superiores A
Priority to ARP070103482A priority Critical patent/AR062239A1/es
Priority to ES08793787T priority patent/ES2385121T3/es
Priority to CA2736382A priority patent/CA2736382A1/en
Priority to AT08793787T priority patent/ATE551072T1/de
Priority to EP08793787A priority patent/EP2186529B1/en
Priority to PCT/MX2008/000104 priority patent/WO2009022897A2/es
Priority to DK08793787.6T priority patent/DK2186529T3/da
Priority to US12/735,659 priority patent/US9023350B2/en
Publication of AR062239A1 publication Critical patent/AR062239A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/47—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having at least one of the sulfo groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmacéutica sinérgica, util para inhibir la neovascularizacion (angiogénesis) corneal y retinal, y de otros organos, en un humano o animal, caracterizada porque comprende, en un vehículo o portador farmacéuticamente aceptable: 60 a 90% en peso de suramina, o el equivalente de una de sus sales farmacéuticamente aceptables; y 40 a 10% en peso de bevacizumab; en donde dichos porcentajes son con respecto a la suma de los pesos de ambos principios activos. Dicha composicion farmacéutica sinérgica se presenta bajo la forma de una composicion inyectable por vía endovenosa, intravítrea o subconjuntival, o bajo la forma para la administracion topica.
ARP070103482A 2007-08-07 2007-08-07 Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal AR062239A1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ARP070103482A AR062239A1 (es) 2007-08-07 2007-08-07 Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
ES08793787T ES2385121T3 (es) 2007-08-07 2008-08-07 Composición farmacéutica sinérgica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal, y de otros órganos, en un humano o animal
CA2736382A CA2736382A1 (en) 2007-08-07 2008-08-07 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal
AT08793787T ATE551072T1 (de) 2007-08-07 2008-08-07 Synerge pharmazeutische zusammensetzung zur hemmung von hornhaut- und netzhaut- neovaskularisation (angiogenese) und in anderen organen eines menschen oder tieres
EP08793787A EP2186529B1 (en) 2007-08-07 2008-08-07 Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal
PCT/MX2008/000104 WO2009022897A2 (es) 2007-08-07 2008-08-07 Composición farmacéutica sinergica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal y de otros órganos en un humano o animal
DK08793787.6T DK2186529T3 (da) 2007-08-07 2008-08-07 Anvendelig synergisk og farmaceutisk sammensætning til hæmning af corneal og retinal neovaskularisering (angiogenese), og i andre organer, hos et menneske eller dyr
US12/735,659 US9023350B2 (en) 2007-08-07 2008-08-07 Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070103482A AR062239A1 (es) 2007-08-07 2007-08-07 Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal

Publications (1)

Publication Number Publication Date
AR062239A1 true AR062239A1 (es) 2008-10-22

Family

ID=39929413

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103482A AR062239A1 (es) 2007-08-07 2007-08-07 Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal

Country Status (8)

Country Link
US (1) US9023350B2 (es)
EP (1) EP2186529B1 (es)
AR (1) AR062239A1 (es)
AT (1) ATE551072T1 (es)
CA (1) CA2736382A1 (es)
DK (1) DK2186529T3 (es)
ES (1) ES2385121T3 (es)
WO (1) WO2009022897A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101847572B1 (ko) 2010-05-28 2018-05-24 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 신혈관신생에 기초한 안 질환 치료용 항-ｃｄ160 특이적 항체
US10296814B1 (en) 2013-06-27 2019-05-21 Amazon Technologies, Inc. Automated and periodic updating of item images data store
US10366306B1 (en) * 2013-09-19 2019-07-30 Amazon Technologies, Inc. Item identification among item variations
PL3151666T3 (pl) 2014-06-03 2020-05-18 Arturo Solis Herrera Modele zwierzęce angiogenezy rogówki oraz chorób rozstrzeniowych rogówki, sposoby wytwarzania i sposoby ich zastosowania
JP2019534269A (ja) 2016-10-14 2019-11-28 ノバルティス アーゲー Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法
EP3979985A4 (en) * 2019-06-07 2023-05-03 Paxmedica, Inc. COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS
WO2022051721A1 (en) * 2020-09-04 2022-03-10 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination compositions and methods for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121320A (en) 1997-02-26 2000-09-19 The University Of Kentucky Research Foundation Combination anti-leukemic therapy by utilizing suramin and biologic response modifiers
WO2006125815A2 (en) * 2005-05-25 2006-11-30 Nycomed Gmbh Tetrahydropyridothiophenes for use in the treatment of cancer
US20070071756A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
FR2953411B1 (fr) 2009-12-03 2012-02-03 Biocodex Combinaison synergique de composes analgesiques

Also Published As

Publication number Publication date
US9023350B2 (en) 2015-05-05
ATE551072T1 (de) 2012-04-15
CA2736382A1 (en) 2009-02-19
EP2186529A2 (en) 2010-05-19
WO2009022897A3 (es) 2009-03-26
ES2385121T3 (es) 2012-07-18
DK2186529T3 (da) 2012-07-16
EP2186529B1 (en) 2012-03-28
US20110076266A1 (en) 2011-03-31
WO2009022897A2 (es) 2009-02-19

Similar Documents

Publication Publication Date Title
AR062239A1 (es) Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
BRPI0509863A (pt) liberação de fármaco para fundo de olho
JP2014505733A5 (es)
CO2018013717A2 (es) Piridinas sustituidas como inhibidores de dnmt1
MX2012006106A (es) Composiciones farmaceuticas que comprenden ligandos de receptores sigma.
UY32602A (es) Formulación para la administración oral de un promotor de apoptosis
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CL2008002542A1 (es) Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
MY157790A (en) Trazodone composition for once a day administration
ECSP13012812A (es) Formulaciones inmunosupresoras
JP2012517449A5 (es)
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
UY35211A (es) Compuestos tricíclicos
BR112015014433A2 (pt) compostos tricíclicos
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BR112013007389A2 (pt) derivado de 1,2,4-triazolona.
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
GT201400042A (es) Compuesto de benzotiazolona

Legal Events

Date Code Title Description
FC Refusal